SLITRK4

Across TCGA pan-cancer cohorts, SLITRK4 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of SLITRK4’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where SLITRK4 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLITRK4 is over-expressed in tumor, although a few such as COAD and KICH show the opposite, repressed pattern.

THCA, COAD, and KICH are the cancer types where SLITRK4 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLITRK4 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	III,IV	+0.949	<.001	9	view →
COAD	Female	All	−0.191	<.001	8	view →
KICH	Female	II,III,IV	−2.221	<.001	7	view →
BLCA	Male	III,IV	−0.557	.014	6	view →
STAD	All	All	−0.373	.002	5	view →
LIHC	Male	All	+0.098	.001	5	view →
HNSC	Male	All	−0.443	.024	3	view →
ESCA	Female	All	−0.716	.018	2	view →
LUAD	Female	III,IV	−0.445	<.001	2	view →
READ	Female	All	−0.438	.021	2	view →
CHOL	All	All	+0.320	.008	2	view →
BRCA	Female	All	−0.255	.016	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

SLITRK4–THCA

Open the THCA breakdown →